The recent dismissal of an antitrust case against Sony relating to the sale of digital video games on the company's PlayStation Store could shed light on the viability of refusal-to-deal claims against platform technology...more
The new Executive Order includes 72 initiatives instructing more than a dozen federal agencies to consider adopting rules intended to enhance competition.
A new Executive Order signed by President Biden includes 72...more
New challenges may lie ahead for the pharmaceutical industry -
What’s next for drug pricing in the US?
Proposals to alter antitrust and patent laws may signal a renewed focus on drug pricing by federal lawmakers,...more
For the thousands of financial institutions anxiously watching the discontinuation and transition from certain interbank offered rates ("IBORs"), 2020 just got a little less chaotic...
...more
On October 7, 2019, California became the first state to enact legislation—Assembly Bill 824 ("AB 824")—rendering certain pharmaceutical patent litigation settlement agreements presumptively anticompetitive. This alert...more
10/18/2019
/ Anti-Competitive ,
Antitrust Violations ,
Burden-Shifting ,
Civil Monetary Penalty ,
Damages ,
Erie Doctrine ,
FTC v Actavis ,
Generic Drugs ,
Hatch-Waxman ,
Judicial Review ,
Patent Litigation ,
Pay-For-Delay ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Popular ,
Rebuttable Presumptions ,
Retroactive Application ,
Reverse Payment Settlement Agreements ,
Rule-of-Reason Analysis ,
State Legislatures